Search research articles
Contact Us
Filters
Showing results (461-470 of 578) with videos related to
Page
of 58
Sort By:
The Lancet. Oncology
|
June 12, 2010
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study
Maaike H Oonk, Bettien M van Hemel, Harry Hollema, et al.
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
Ana Oaknin, Bradley J Monk, Ignace Vergote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium
Nicole Concin, Ioana Braicu, Pierre Combe, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2018
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Patrick Neven, Lynn Jongen, Anneleen Lintermans, et al.
Breast Cancer Research and Treatment
|
June 27, 2007
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study
Patrick Neven, Robert Paridaens, Gino Pelgrims, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
David S Hong, Nicole Concin, Ignace Vergote, et al.
Gynecologic Oncology
|
October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Page
of 58
Search research articles
Search
Showing results (461-470 of 578) with videos related to
Sort By:
Page
of 58
The Lancet. Oncology
|
June 12, 2010
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study
Maaike H Oonk, Bettien M van Hemel, Harry Hollema, et al.
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
Ana Oaknin, Bradley J Monk, Ignace Vergote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium
Nicole Concin, Ioana Braicu, Pierre Combe, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2018
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Patrick Neven, Lynn Jongen, Anneleen Lintermans, et al.
Breast Cancer Research and Treatment
|
June 27, 2007
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study
Patrick Neven, Robert Paridaens, Gino Pelgrims, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
David S Hong, Nicole Concin, Ignace Vergote, et al.
Gynecologic Oncology
|
October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Page
of 58